Cargando…

Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface

SIMPLE SUMMARY: Neuroblastoma is the commonest solid tumour of early childhood. Most children presenting with advanced disease have a poor survival rate, despite intensive chemotherapy treatment. One third of advanced NB tumours have MYCN oncogene amplification and overexpression, which predicts poo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massudi, Hassina, Luo, Jie-Si, Holien, Jessica K., Gadde, Satyanarayana, Krishan, Sukriti, Herath, Mika, Koach, Jessica, Stevenson, Brendan W., Gorman, Michael A., Venkat, Pooja, Mayoh, Chelsea, Luo, Xue-Qun, Parker, Michael W., Cheung, Belamy B., Marshall, Glenn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046377/ https://www.ncbi.nlm.nih.gov/pubmed/36980710 http://dx.doi.org/10.3390/cancers15061822

Ejemplares similares

Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis
por: Sutton, Selina K., et al.
Publicado: (2019)

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
por: Nagy, Zsuzsanna, et al.
Publicado: (2021)

A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
por: Cheung, Belamy B., et al.
Publicado: (2021)

TRIM16 Acts as an E3 Ubiquitin Ligase and Can Heterodimerize with Other TRIM Family Members
por: Bell, Jessica L., et al.
Publicado: (2012)

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4
por: Xue, Chengyuan, et al.
Publicado: (2016)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma
por: Hu, Xinjie, et al.
Publicado: (2019)

Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells
por: Park, Ji Hyun, et al.
Publicado: (2014)

Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
por: Müller, Inga, et al.
Publicado: (2014)

MYCN protein stability is a better prognostic indicator in neuroblastoma
por: Yang, Yi, et al.
Publicado: (2022)

Age-Associated Changes In Oxidative Stress and NAD(+) Metabolism In Human Tissue
por: Massudi, Hassina, et al.
Publicado: (2012)

Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN
por: Pan, Chunyu, et al.
Publicado: (2021)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells
por: O’Brien, Eleanor M., et al.
Publicado: (2018)

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma
por: Boboila, Shuobo, et al.
Publicado: (2018)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma
por: Eberhardt, Allison, et al.
Publicado: (2016)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

DockNet: high-throughput protein–protein interface contact prediction
por: Williams, Nathan P, et al.
Publicado: (2022)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022)

NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas
por: Suenaga, Yusuke, et al.
Publicado: (2014)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation
por: De Wyn, Jolien, et al.
Publicado: (2021)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study
por: D’Silva, Arlene M., et al.
Publicado: (2023)

Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma
por: Bell, Jessica L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hkucmgp53dta0j0cvnmiiiiog7